Can a new drug cool down inflamed arteries and prevent heart attacks?

NCT ID NCT06263244

Ongoing Disease control Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 07, 2026 · Updated 4 times

Summary

This phase 3 trial tests whether ziltivekimab, a drug that targets inflammation, can reduce swelling in the arteries of 40 people with coronary artery disease. Participants receive either the drug or a placebo, and researchers use advanced imaging and blood tests to measure changes. The goal is to see if this approach can lower inflammation, which is linked to heart attacks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ziltivekimab (a monoclonal antibody targeting IL-6)
What this could lead to: If it works, this could point toward a treatment that lowers inflammation in arteries, potentially reducing heart attack risk.
What could go wrong: This is a small, early-phase trial focused on imaging and lab markers, not clinical outcomes like heart attacks. The drug may not show clear benefits or could have side effects like infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATHEROSCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atherosclerosis coronary artery disorder Inflammation inflammatory disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATHEROSCLEROSIS INFLAMMATION

Contacts and locations

Locations

Amsterdam UMC, location AMC

Amsterdam, 1105AZ, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.